Archive

Ozone raises risk of acute respiratory disease syndrome in critically ill patients

by Bruce Sylvester: Ozone exposure appears to be associated with acute respiratory disease syndrome (ARDS) in some critically ill patients, according to research published on Dec. 17, 2015… read more.

ASH 2015 Video Interview by Esther Drain: Association of gene expression profiling, Interim PET, EBV status and PD-L1 expression in cHL. An interview with Dr Cathy Burton (Clinical Haematologist, Leeds Teaching Hospitals, UK)

ASH 2015 Video Interview by Esther Drain: Is oral as effective as IV or sub cutaneous administration? Professor Philippe Moreau (University Hospital, Nantes, France), Professor Gordon Cook (Leeds Teaching Hospitals, UK) and Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) discuss whether the trend towards new oral agents for myeloma will mean a choice between efficacy and convenience… or in fact whether both can be achieved

ASH 2015: TOURMALINE: Professor Philippe Moreau (University Hospital, Nantes, France) discusses the Tourmaline study – ixazomib, lenalidomide, dexamethasone (iRd) in R/R myeloma, with opinions on the data from Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK), Professor Gordon Cook (Leeds Teaching Hospitals, UK), Erik Low (Chief Executive Myeloma UK) and Dr Shaji Kumar (Mayo Clinic, Rochester, USA)

Ixazomib improves progression-free survival across subgroups by Thomas R. Collins: The oral proteasome inhibitor (PI) ixazomib with lenalidomide and dexamethasone (IRd) performed well versus placebo plus lenalidomide and… read more.

ASH 2015 Video Interview by Esther Drain: Erik Low (Chief Executive Myeloma UK), Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) and Professor Gordon Cook (Leeds Teaching Hospitals, UK) discuss how and when we might expect our patients to have access to the therapies now available to US myeloma patients

ASH 2015: Clinical discussant in this ASH/FDA session, Professor Paul Richardson (Harvard medical School, Boston, USA), discusses the clinical relevance of the new oral proteazome inhibitor ixazomib and two new monoclonal antibodies daratumumab and elotuzumab approved in the last few weeks by the FDA

Experts try to provide clarity in dizzying myeloma landscape by Thomas R. Collins: There’s no doubt that the bonanza of new multiple myeloma therapies is a blessing to… read more.

ASH 2015: Interview with Professor Sagar Lonial (Emory University School of Medicine, Atlanta, GA, USA) gives a flavour of the excitement generated at ASH

ASH 2015 proved to be all that we’d hoped for! We’ve witnessed unprecedented change in multiple myeloma with CR and VGPR percentages higher than ever… and most of this… read more.

ASH 2015: New therapies explored in peripheral T-cell lymphoma

by Thomas R. Collins: In early results, patients newly diagnosed with peripheral T-cell lymphoma (PTCL) treated with the HDAC-inhibitor belinostat, and CHOP therapy, tolerated the combination well at… read more.

ASH 2015: Early findings on oral therapies for relapsed/refractory DLBCL unveiled

by Thomas R. Collins: Early results show that venetoclax, a BCL-2-inhibitor, produced relatively good response rates in relapsed or refractory non-Hodgkin lymphoma (NHL) patients.1

ASH 2015: Risk profile key in transplant decisions in non-Hodgkin lymphoma

by Thomas R. Collins: There could be a role for consolidation autologous stem cell transplantation for patients with diffuse, aggressive non-Hodgkin lymphomas (NHL) who are at high risk… read more.

ASH 2015: Investigators update results on key carfilzomib studies: ENDEAVOR and ASPIRE

by Thomas R. Collins: A subgroup analysis of data from the ENDEAVOR trial, comparing carfilzomib and dexamethasone (Kd) to bortezomib and dexamethasone (Vd) — shows improved progression-free survival (PFS)… read more.

ASH 2015: Ixazomib shows promise in variety of settings, according to early trial results

by Thomas R. Collins: Fresh off its approval in the U.S. in the relapsed/refractory setting of multiple myeloma, ixazomib continues to be examined in other patient pools, with… read more.